Anti-ischaemic effect of ivabradine

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Roberto FerrariClaudio Ceconi

Abstract

Ivabradine, the first representative of a new class of exclusive heart rate-reducing agents, selectively inhibits the I(f) current in the sinoatrial node. The direct electrophysiological consequence of this inhibition is a reduction in the slope of the diastolic depolarisation curve and a decrease in heart rate. Pharmacological inhibition of the I(f) current with ivabradine has been shown to preserve coronary vasodilatation upon exercise, i.e., myocardial perfusion, with no negative inotropic effects and maintenance of cardiac contractility. Ivabradine protects the myocardium during ischaemia, improves left ventricular function in congestive heart failure, and reduces remodelling subsequent to myocardial infarction. Pure heart rate reduction by specific and selective I(f) inhibition decreases oxygen demand, improves myocardial energetics and improves perfusion of the ischaemic myocardium. We can expect distinct clinical benefits from long-term heart rate reduction in patients with chronic ischaemic disease.

Citations

Feb 8, 2007·Cardiovascular Drugs and Therapy·Houman Ashrafian, Michael P Frenneaux
Apr 9, 2009·Journal of Bioenergetics and Biomembranes·H Lemieux, C L Hoppel
Jan 24, 2009·Advances in Therapy·Graziano RiccioniNicolantonio D'Orazio
Sep 13, 2012·Heart Failure Reviews·Moritz OsterholtTorsten Doenst
Aug 30, 2011·The International Journal of Biochemistry & Cell Biology·Hélène LemieuxErich Gnaiger
Nov 19, 2011·British Journal of Pharmacology·Martina Del LungoElisabetta Cerbai
Sep 29, 2009·American Heart Journal·Ralf KösterUNKNOWN REDUCTION Study Group
Jul 11, 2016·International Journal of Cardiology·Song-Young ParkRussell S Richardson
Oct 13, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Alexandre SarreEric Raddatz
Nov 9, 2016·Case Reports in Neurological Medicine·Giuliano Ohde DalledoneRosana Herminia Scola
Feb 1, 2011·Therapeutic Advances in Drug Safety·Gordon F RushworthStephen J Leslie
Nov 27, 2008·Journal of Cardiovascular Pharmacology·Fanny VaillantPhilippe Chevalier
Feb 13, 2009·Expert Review of Cardiovascular Therapy·Graziano Riccioni
Feb 26, 2013·British Journal of Haematology·Andranik A Aprikyan, Zaza Khuchua
Nov 29, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Dingding XiongZaza Khuchua
Oct 23, 2018·Medicina·Marlon E Cerf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.